Last reviewed · How we verify
iGlarLixi
iGlarLixi is a Insulin/GLP-1 receptor agonist combination Small molecule drug developed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. It is currently FDA-approved for Type 2 diabetes mellitus. Also known as: glargine insulin / lixisenatide.
iGlarLixi is a fixed-ratio combination of insulin glargine and lixisenatide that lowers blood glucose by providing basal insulin coverage and enhancing insulin secretion via GLP-1 receptor activation.
iGlarLixi is a fixed-ratio combination of insulin glargine and lixisenatide that lowers blood glucose by providing basal insulin coverage and enhancing insulin secretion via GLP-1 receptor activation. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | iGlarLixi |
|---|---|
| Also known as | glargine insulin / lixisenatide |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Drug class | Insulin/GLP-1 receptor agonist combination |
| Target | Insulin receptor; GLP-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin glargine provides long-acting basal insulin replacement to control fasting and between-meal blood glucose levels. Lixisenatide is a GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, slows gastric emptying, and reduces glucagon secretion, thereby improving postprandial glucose control. The combination addresses both fasting and postprandial hyperglycemia in a single injection.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Nausea
- Vomiting
- Injection site reactions
- Headache
Key clinical trials
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus (PHASE4)
- Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents (PHASE4)
- Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease (PHASE4)
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus (PHASE4)
- The Efficacy of Mallya in Type 2 Diabetes Transiting From Oral Antidiabetic Drugs to iGlarLixi (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iGlarLixi CI brief — competitive landscape report
- iGlarLixi updates RSS · CI watch RSS
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School portfolio CI
Frequently asked questions about iGlarLixi
What is iGlarLixi?
How does iGlarLixi work?
What is iGlarLixi used for?
Who makes iGlarLixi?
Is iGlarLixi also known as anything else?
What drug class is iGlarLixi in?
What development phase is iGlarLixi in?
What are the side effects of iGlarLixi?
What does iGlarLixi target?
Related
- Drug class: All Insulin/GLP-1 receptor agonist combination drugs
- Target: All drugs targeting Insulin receptor; GLP-1 receptor
- Manufacturer: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: glargine insulin / lixisenatide
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing